Last reviewed · How we verify

NCT05661175

Application of One-handed Lithotripsy in Percutaneous Nephrolithotomy

Status unknown NA Last updated 28 March 2023
What this trial tests

NA trial testing one-handed technique in Percutaneous Nephrolithotomy in 100 participants. Status unknown.

Timeline
3 December 2022
Primary endpoint
3 November 2023
3 November 2023

Quick facts

Lead sponsorThe First Affiliated Hospital of University of South China
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date3 December 2022
Primary completion3 November 2023
Estimated completion3 November 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital of University of South China

Who can join

Adults 18 to 80, any sex, with Percutaneous Nephrolithotomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Percutaneous nephrolithotomy(PCNL) is a surgical method for upper urinary calculi.Traditional percutaneous nephrolithotomy usually requires the lithotripsy with the left hand holding the nephroscope and the right hand adjusting the laser fiber,which requires a lot of practice to master this technique.The goal of this study is to explore the safety and effectiveness of the PCNL with one-handed lithotripsy technique

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Percutaneous Nephrolithotomy

Currently open trials in the same condition.

Other The First Affiliated Hospital of University of South China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05661175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing